Free Webex Call
The Diaphragm Pacing Therapy System Market was valued at USD 7.71 Billion in 2024, and is expected to reach USD 9.71 Billion by 2030, rising at a CAGR of 4.06%. The Global Diaphragm Pacing Therapy System Market has witnessed steady growth in recent years, driven by factors such as the rising prevalence of respiratory disorders, technological advancements in medical devices, and increasing awareness about diaphragm pacing as an alternative therapy for certain patient populations. For instance, in Europe, respiratory disorders rank as the third leading cause of death in European Environment Agency member countries. Annually, nearly 420,000 deaths are attributed to respiratory diseases, with over 60% linked to Chronic Respiratory Diseases (CRDs) (Eurostat, 2024a; WHO, 2024; IHME, 2024). While certain countries experience higher mortality and disease burden from respiratory conditions, no consistent regional pattern has been identified. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Key Market Drivers
Rising Prevalence of Respiratory Disorders
The global healthcare landscape is witnessing a significant shift, with a concerning increase in the prevalence of respiratory disorders. These conditions can significantly impair an individual's ability to breathe, leading to a reduced quality of life and, in severe cases, life-threatening situations. However, amidst these challenges, there is a glimmer of hope for patients in the form of diaphragm pacing therapy systems.As the prevalence of respiratory disorders continues to rise, the diaphragm pacing therapy system market is poised for substantial growth. According to WHO, chronic obstructive pulmonary disease (COPD) claims over 3 million lives annually, silently impacting more than 380 million people worldwide. As the fourth leading cause of death globally, COPD has remained underrepresented in global health discussions, despite its profound effects on patients and families. It’s time to bring this noncommunicable disease to the forefront and address its devastating impact.
Key Market Challenges
High Initial Costs
One of the most prominent challenges in the diaphragm pacing therapy system market is the high initial costs associated with these devices. The sophisticated technology and intricate surgical procedures required for implantation can result in substantial expenses for both healthcare facilities and patients. The cost may act as a deterrent, limiting access to those who may benefit from diaphragm pacing therapy.Key Market Trends
Enhanced Device Technology
One of the most prominent trends in the diaphragm pacing therapy system market is the ongoing enhancement of device technology. Manufacturers are investing in research and development to create more advanced, efficient, and patient-friendly systems. This includes devices with improved battery life, wireless connectivity for remote monitoring, and more compact designs for enhanced comfort.Key Market Players
- LUNGPACER MEDICAL INC.
- Avery Biomedical Devices, Inc.
- Synapse Biomedical Inc
- Astrotech Corp.
- AstraZeneca PLC
- Novartis AG
- Boehringer Ingelheim
- Respironics Ltd
- Johnson & Johnson (Actelion)
- PneumRx, LLC
Report Scope:
In this report, the Global Diaphragm Pacing Therapy System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Diaphragm Pacing Therapy System Market, By Product:
- External Diaphragm Pacemaker
- Diaphragm Pacemaker
Diaphragm Pacing Therapy System Market, By Application:
- Spinal Cord Injury
- Amyotrophic Lateral Sclerosis
- Others
Diaphragm Pacing Therapy System Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Diaphragm Pacing Therapy System Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Global Diaphragm Pacing Therapy System Market Outlook
6. North America Diaphragm Pacing Therapy System Market Outlook
7. Europe Diaphragm Pacing Therapy System Market Outlook
8. Asia-Pacific Diaphragm Pacing Therapy System Market Outlook
9. South America Diaphragm Pacing Therapy System Market Outlook
10. Middle East and Africa Diaphragm Pacing Therapy System Market Outlook
11. Market Dynamics
12. Market Trends & Developments
13. Porter’s Five Forces Analysis
14. Competitive Landscape
Companies Mentioned
- LUNGPACER MEDICAL INC.
- Avery Biomedical Devices, Inc.
- Synapse Biomedical Inc
- Astrotech Corp.
- AstraZeneca PLC
- Novartis AG
- Boehringer Ingelheim
- Respironics Ltd
- Johnson & Johnson (Actelion)
- PneumRx, LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 185 |
| Published | March 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 7.71 Billion |
| Forecasted Market Value ( USD | $ 9.71 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
